Top Markets
Coin of the day
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
Rang in aandelen #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Aandeelprijs
$0.30221445
Laatst gesynchroniseerd: 2023-05-22
Marktkapitalisatie
$2.49M
Verandering (1 dag)
-0.10%
Verandering (1 jaar)
0.00%
Land
FR
Handel Lysogene S.A. (LYS)

Categorie

Dividendrendementgeschiedenis voor Lysogene S.A. (LYS)
Het dividendrendement (TTM) van Lysogene S.A. (aandelsymbool: LYS) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Lysogene S.A. (LYS) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten